HORMONE CONNECTION ESTROGEN SUPPORT
Natural health product licensed in Canada
- Licence holder
- IHH Products Division Inc.
- NPN or DIN-HM
- 80071026
- Status
- Inactive licence
- Licence date
- 12 July 2016
- Revision date
- Not provided
- Form
- Capsule
- Route of administration
- Orale
- Application type
- Non traditionnelle
If this product were sold in France
- Conditions légales
Actaea racemosa L.: Seuls les extraits aqueux et hydro-alcooliques de titre faible (30 %) sont admis. La portion journalière recommandée ne doit pas conduire à une ingestion de glycosides de triterpène (calculés comme 27-déoxyactéine) supérieure à 3 mg.
arrêté du 24 juin 2014, annexe I. French orders of 9 May 2006 (nutrients), 24 June 2014 (plants) and 26 September 2016 (other substances), consolidated LEGI collection, retrieved 23 October 2026.
- Conditions légales
Trifolium pratense L.: La portion journalière recommandée ne doit pas conduire à une ingestion d'isoflavones supérieure à 1 mg/kg de poids corporel (exprimés comme aglycone du composant principal). L'étiquetage doit comporter un avertissement déconseillant l'usage chez les femmes ayant des antécédents personnels ou familiaux de cancer du sein.
arrêté du 24 juin 2014, annexe I. French orders of 9 May 2006 (nutrients), 24 June 2014 (plants) and 26 September 2016 (other substances), consolidated LEGI collection, retrieved 23 October 2026.
- Conditions légales
Ginkgo biloba L.: L'étiquetage des compléments alimentaires qui contiennent la feuille de la plante Ginkgo biloba L. doit comporter un avertissement avec la teneur suivante: "Consultez votre médecin en cas de prise simultanée d'anticoagulants."
arrêté du 24 juin 2014, annexe I. French orders of 9 May 2006 (nutrients), 24 June 2014 (plants) and 26 September 2016 (other substances), consolidated LEGI collection, retrieved 23 October 2026.
- Conditions légales
Foeniculum vulgare Mill.: La portion journalière recommandée ne doit pas conduire à une ingestion d'estragole supérieure à 0,05 mg/kg de poids corporel pour les enfants de moins de 12 ans.
arrêté du 24 juin 2014, annexe I. French orders of 9 May 2006 (nutrients), 24 June 2014 (plants) and 26 September 2016 (other substances), consolidated LEGI collection, retrieved 23 October 2026.
A daily quantity is calculated only for an explicit adult oral dosage, stated per day and in a solid unit matching the product form. Ambiguous units, liquids, powders and paediatric doses are not extrapolated. A quantity not calculated is not compared with dose limits. This analysis does not constitute authorisation for sale in France or an assessment of safety or efficacy.
Composition
| Medicinal ingredient and source | Per dosage unit, according to the source | Maximum per day, adult |
|---|---|---|
| Actaea racemosa Source : Racine et rhizome Extract : Matériel brut sec Extraction ratio : 4:1 Dry plant equivalent : 200 milligramme Potency : 2.5 % Triterpene glycosides | 50 milligramme | Not calculated |
| Trifolium pratense Source : Sommité Extract : Matériel brut sec Extraction ratio : 100:1 Dry plant equivalent : 2,000 milligramme Potency : 4 milligramme Biochanin A | 200 milligramme | Not calculated |
| Ginkgo biloba Source : Feuille Extract : Matériel brut sec Extraction ratio : 50:1 Dry plant equivalent : 3,000 milligramme Potency : 6 % Terpene lactones | 60 milligramme | Not calculated |
| Ginkgo biloba Source : Feuille Potency : 24 % Flavonoid glycosides | Not specified | Not calculated |
| Foeniculum vulgare Source : Fruit Extract : Matériel brut sec Extraction ratio : 4:1 Dry plant equivalent : 400 milligramme | 100 milligramme | Not calculated |
| Angelica sinensis Source : Racine Extract : Matériel brut sec Extraction ratio : 10:1 Dry plant equivalent : 2,000 milligramme Potency : 1 % Ligustilide | 200 milligramme | Not calculated |
| Trifolium pratense Source : Sommité Potency : 4 milligramme Genistein | Not specified | Not calculated |
| Trifolium pratense Source : Sommité Potency : 4 milligramme Daidzein | Not specified | Not calculated |
| Trifolium pratense Source : Sommité Potency : 4 milligramme Formononetin | Not specified | Not calculated |
Non-medicinal ingredients
Hypromellose
Recommended doses in Canada
| Population | Age | Quantity per serving | Frequency |
|---|---|---|---|
| Femmes ménopausées et en postménopause | Not specified | 1 Capsule | 2 Tous les jours |
Uses authorised in Canada
Used in Herbal Medicine to help relieve the pain associated with menstruation. Used in Herbal Medicine to help relieve muscle and joint pain associated with rheumatic conditions. Used in Herbal Medicine to help ease nervous tension (calmative). Used in Herbal Medicine to help relieve premenstrual symptoms. Help(s) relieve symptoms associated with menopause. May reduce severe and frequent menopausal symptoms (such as hot flashes/flushes and/or night sweats). Helps to enhance cognitive function in adults. Helps to enhance memory in adults. Helps to support peripheral circulation. Used in Traditional Chinese Medicine (TCM) to invigorate and harmonize/tonify the blood.
A use authorised in Canada is not an authorised health claim in the European Union. See the health claims register.
Warnings in Canada
- Effets indésirables connus
If you experience breast pain, discomfort and/or tenderness, discontinue use and consult a health care practitioner.
- Précautions et mises en garde
Consult a health care practitioner if symptoms persist or worsen. Consult a health care practitioner prior to use if you are breastfeeding. Consult a health care practitioner prior to use if you have a liver disorder or develop symptoms of liver trouble. Consult a health care practitioner prior to use if you are taking medications for diabetes, high blood pressure, or seizures. If you are taking birth control pills, consult a health care practitioner prior to use. If you are taking hormone replacement therapy (HRT), consult a health care practitioner prior to use. If you are taking thyroid hormone replacement therapy, consult a health care practitioner prior to use. If you have a liver disorder or develop liver-related symptoms (e.g. abdominal pain, jaundice, dark urine), consult a health care practitioner prior to use. If you have a history of hormonal or gynecological disease including ovarian cancer, endometriosis and/or uterine fibroids, consult a health care practitioner prior to use. Ensure that you are up-to-date on appointed clinical tests such as mammograms and endometrial ultrasounds or biopsies before using this product. If you experience breast pain, discomfort, soreness and/or tenderness, abnormal uterine bleeding including spotting and/or recurrence of menstruation in postmenopausal women, discontinue use and consult a health care practitioner. If symptoms worsen, consult a health care practitioner. If you have family history of cancer, consult a health care practitioner prior to use.
- Contre-indications
Do not use if you are pregnant. Do not use if you are taking health products that affect blood coagulation (e.g. blood thinners, clotting factor replacements, acetylsalicylic acid, ibuprofen, fish oils, vitamin E) as this may increase the risk of spontaneous bleeding. If you have allergy/hypersensitivity to members of the Apiaceae/Umbelliferae family (anise, caraway, carrot, celery, dill, parsley), do not use this product. If you have diarrhoea or haemorrhagic diseases, do not use this product. If you currently have or previously had breast cancer or if you have a predisposition to breast cancer, as indicated by an abnormal mammogram and/or biopsy, or if you have a family member with breast cancer, do not use this product. Avoid prolonged exposure to sunlight, ultraviolet light (UV) or UV therapy. If menstruation is delayed or absent, or if you experience increased menstrual bleeding time, discontinue use and consult a health care practitioner. If you have hyper menorrhoea, profuse menstrual flow / heavy period do not use this product.
Source
Official Health Canada record, licence 80071026
Licensed Natural Health Products Database (LNHPD), Health Canada: licensed products, ingredients, doses, uses and risks, retrieved 27 October 2026.
Contains information licensed under the Open Government Licence – Canada (Health Canada, LNHPD)
Licence du gouvernement ouvert – Canada 2.0 (OGL-Canada 2.0)
The formula sold in Europe under the same name may differ. This information does not replace advice from a doctor or pharmacist.
The evidence date of this ingredient list is unknown.
Has the product changed? Photograph the packaging.